IPO
-
-
-
-
-
-
-
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
-
-
-
-
-
-
-
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
-
-
-
-
-
-
-
Ascentage Pharma to Participate in Evercore China Biotech Summit
-
-
-
-
-
-
-
Ascentage Pharma gets China approval for cancer drug lisaftoclax
-
-
-
-
-
-
-
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
-
-
-
-
-
-
-
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
-
122,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

